Evidence map›Paper›PMID 41347092›Full record

ArticleFrontiers in oncology2025

CldU sensitizes

Nawel Zouggari, Camilla Trugenberger, Valentine Du Bois, Wenwen Wang, Giacomo G Rossetti, Thanos D Halazonetis, Intidhar Labidi-Galy

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Nawel Zouggari *Department of Medicine and Center of Translational Research in Onco-Hematology, Faculty of Medicine, University of Geneva, Geneva, Switzerland.
Camilla Trugenberger *Department of Medicine and Center of Translational Research in Onco-Hematology, Faculty of Medicine, University of Geneva, Geneva, Switzerland.
Valentine Du BoisDepartment of Medicine and Center of Translational Research in Onco-Hematology, Faculty of Medicine, University of Geneva, Geneva, Switzerland.
Wenwen WangDepartment of Medicine and Center of Translational Research in Onco-Hematology, Faculty of Medicine, University of Geneva, Geneva, Switzerland.
Giacomo G RossettiDepartment of Molecular and Cellular Biology, Faculty of Sciences, University of Geneva, Geneva, Switzerland.
Thanos D HalazonetisDepartment of Molecular and Cellular Biology, Faculty of Sciences, University of Geneva, Geneva, Switzerland.
Intidhar Labidi-GalyDepartment of Medicine and Center of Translational Research in Onco-Hematology, Faculty of Medicine, University of Geneva, Geneva, Switzerland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PARP inhibitors are widely used class of drugs for the treatment of homologous recombination deficient cancers, including

Indexed as

BRCA mutationcancerCldUPARP inhibitorresistancereversion mutationthymidine analogue

Identifiers

PMID41347092
PMCPMC12672267

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.